![](https://endpts.com/wp-content/uploads/2021/09/Peter-Marks-AP-tile-scaled.jpg)
Peter Marks (Jim Lo Scalzo/Pool via AP Images)
FDA's CBER chief hints at expanding Sarepta's gene therapy label, sends stock up 25%
Despite a failed confirmatory trial announced in October, the FDA’s Peter Marks, the top regulator for all cell and gene therapies in the US, is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.